Heron Therapeutics (FRA:AXD2) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.38
GF Value €1.26
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Heron Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:AXD2 vs PLYX, ORMP, SPRO: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Heron Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 70.1% below its estimated GF Value™ of €1.26. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €1.26 vs. price of €0.38 (70.1% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€1.26
GF Value